Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
THOC1 CRISPR Activation Plasmid (h): sc-403390-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- THOC1 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- THOC1 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by THOC1 CRISPR Activation Plasmid (h) and THOC1 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the THOC1 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: THOC1 Antibody (E-10): sc-514123
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
THOC1 CRISPR Activation Plasmid (h) | sc-403390-ACT | 20 µg | $397.00 |
THOC1 encodes a core subunit of the THO/TREX complex that couples RNA polymerase II transcription with pre-mRNA processing and mRNA export through the nuclear pore. By coordinating messenger ribonucleoprotein (mRNP) assembly, THOC1 supports transcriptome integrity, limits R-loop accumulation, and contributes to genome stability during replication and DNA damage responses. Perturbation of THO/TREX components has been linked to transcription-associated genomic instability and altered expression programs that are frequently studied in cancer biology and other proliferative or stress-responsive contexts. Human THOC1 is therefore widely used as a mechanistic entry point for investigating transcription–export coupling, RNA surveillance, and chromatin-associated RNA processing.
THOC1 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous THOC1 expression without altering the underlying DNA sequence.
THOC1 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the THOC1 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the THOC1 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous THOC1 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native THOC1 locus and enabling the study of THOC1-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of THOC1 pathway restoration in tumor cells with silenced or reduced THOC1 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.